×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
Privacy
Articles
Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
The Manufacturing Costs and Supply Chain Dynamics of Diabetes Drugs
Novo Nordisk's Stance on Semaglutide for Cosmetic Use
Managing Blood Sugar with GLP-1 Medications: Foods to Avoid and Healthier Alternatives
The Economic Impact of Ozempic on Denmark
Studies of Cinnamon for Blood Sugar Control: Mixed Results with No Clear Answer
Tirzepatide and the Future of Incretin Therapies: A New Horizon in Obesity Treatment
Managing Type 2 Diabetes: The Power of Combining GLP-1 Medicines with FreeStyle Libre Technology
Viewing Type 2 Diabetes as a Vascular Disease
How an Hour-by-Hour View Transforms Time in Range Insights
Exploring the Neuroprotective Potential of GLP-1: A New Frontier in Medical Research
Public Perception of Obesity and Weight-Loss Drugs
GLP-1 Receptor Agonists: A New Hope for Obstructive Sleep Apnea and Chronic Kidney Disease
Understanding Obesity: Beyond the Scale
How Well Do My CGM and BGM Readings Match?
Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
Join the 5K@ADA Virtual Run/Walk for Diabetes Awareness 2024
Mounjaro: A New Player in the GLP-1 Arena for Type 2 Diabetes Management
Diabetes and Eye Health
Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
News
October 2025
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results
September 2025
CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
August 2025
FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
Top Subjects
Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
